[Skip to Content]
[Skip to Content Landing]
Views 183
Citations 0
Comment & Response
January 2018

Interpretation of the ATHENA Trial—Caveats and Future Directions

Author Affiliations
  • 1Centre d’Investigation Clinique Plurithématique 1433, INSERM U1116, Université de Lorraine, CHRU de Nancy, Nancy, France
JAMA Cardiol. 2018;3(1):89-90. doi:10.1001/jamacardio.2017.4370

To the Editor We read with interest the article published in JAMA Cardiology titled “Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial” by Butler et al.1 However, we would like to point out some caveats in this study and suggest improvements for future acute heart failure (AHF) trials involving mineralocorticoid receptor antagonists.

First Page Preview View Large
First page PDF preview
First page PDF preview